Orphan drug market access, Marketing & Sales services in PL, HU, CZ, SK
- Local in-country market research and data analysis
We research the local market - without relaying on simple extrapolations - for disease incidences and prevalence figures, talk to doctors, KOLs and patient organizations to gauge opportunities for your product.
- Development of market access & pricing strategy plan
We develop market access plans including the possibility of named patient imports and give you a clear guidance how the market can be accessed and when patients could get on paid treatment. We check product price sensitivity taking local financial rules and regulations into account.
- Local regulatory affairs
We make sure that your products comply with local requirements, add labeling and information leaflets if appropriate.
- Health Technology Assessment (HTA) & reimbursement preparation
We compile the country specific, local language based reimbursement documentation and adapt value dossiers to fit regional HTA rules and requirements.
- Named Patient Import evaluation
We provide scientific liaison services and negotiate a patient-by-patient access with National Health Insurance Funds in collaboration with medical prescribers. Usually the product must be registered in at least one Western style country in order to start named patient imports and get a named patient financed access granted.
- Patient finding campaigns
We organize awareness campaigns where appropriate and work with the local medical community to find and identify new patients suitable for niche and orphan drugs therapeutic approaches. Our teams gained a reputation to be a reliable and helpful partner. Pharmacenter helps to find rare disease patients for phase 2/phase 3 studies leveraging our Eastern European network of partners, rare disease KOLs and treatment centers.
- Marketing & Sales of Orphan Drugs
Our country managers have been working formerly for orphan drug and pharmaceutical companies like Shire, SOBI, AstraZeneca and have a proven track record in selling orphan drugs and niche products. We provide a one-stop-shop, highly efficient and cost-effective way to commercialize rare disease products.
We provide pharmacovigilance services for all countries we work in and ensure that every adverse drug reaction is collected in compliance with the local regulation. Data are archived to be accessible by the Regulatory Agencies and partner companies. We are working according to highest international industry standards and national codes of practice.